Member Exclusive News

Transformative cholesterol-lowering drug acquired as part of $9.7 billion merger

Novartis (Basel, Switzerland) is set to acquire The Medicine Company (NJ, USA) for a price of $9.7 billion. Under the terms of the agreement, Novartis will also add inclisiran, a novel cholesterol-lowering drug, into their portfolio.

Go to the profile of Zoe Campbell
Nov 25, 2019

Please sign in or register for FREE

No comments yet.